TumCMig Cancer Research Results

TumCMig, Tumor cell migration: Click to Expand ⟱
Source:
Type:
Tumor cell migration is a critical process in cancer progression and metastasis, which is the spread of cancer cells from the primary tumor to distant sites in the body.
Scientific Papers found: Click to Expand⟱
2988- RES,    The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation
- in-vitro, HCC, HUH7
TumCMig↓, TumCI↓, uPA↓, Sp1/3/4↓,
1747- RosA,    Molecular Pathways of Rosmarinic Acid Anticancer Activity in Triple-Negative Breast Cancer Cells: A Literature Review
- Review, BC, MDA-MB-231 - Review, BC, MDA-MB-468
TumCCA↑, TNF-α↑, GADD45A↑, BNIP3↑, survivin↓, Bcl-2↓, BAX↑, HH↓, eff↑, ChemoSen↑, RadioS↑, TumCP↓, TumCMig↓, Apoptosis↑, RenoP↑, CardioT↓,
1048- RosA,  Ger,    Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis
- in-vivo, Colon, MC38
TumCMig↓, TumCI↓, PD-1↓, COX2↓, PD-L1↓,
3016- RosA,    Rosmarinic Acid Inhibits Cell Growth and Migration in Head and Neck Squamous Cell Carcinoma Cell Lines by Attenuating Epidermal Growth Factor Receptor Signaling
- in-vitro, HNSCC, UM-SCC-6 - in-vitro, HNSCC, UM-SCC-10B
chemoP↓, EGF↓, tumCV↓, TumCMig↓, ROS↓, PI3K↓, Akt↓, ERK↓, antiOx↑, p‑EGFR↓,
3027- RosA,    Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway
- in-vitro, HCC, SMMC-7721 cell
TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, TumCMig↓, MMPs↓, Vim↓,
3008- RosA,    Rosmarinic acid decreases viability, inhibits migration and modulates expression of apoptosis-related CASP8/CASP3/NLRP3 genes in human metastatic melanoma cells
- in-vitro, Melanoma, SK-MEL-28
tumCV↓, TumCMig↓, ROS↓, Casp3↑, selectivity↑, Casp8↑, NLRP3↓,
3035- RosA,    Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling
- in-vitro, PC, NA - in-vivo, NA, NA
Gli1↓, TumCCA↑, TumCMig↓, TumCI↓, CDK2↓, cycE/CCNE↓, P21↑, p27↑,
1132- RT,    Rutin Promotes Proliferation and Orchestrates Epithelial–Mesenchymal Transition and Angiogenesis in MCF-7 and MDA-MB-231 Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
Vim↑, N-cadherin↑, E-cadherin↓, TumCP↑, TumCMig↑, tumCV↑, MKI67↑,
4900- Sal,    Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications
- Review, BC, NA
CSCs↓, Apoptosis↑, TumAuto↑, necrosis↑, TumCP↓, TumCI↓, TumCMig↓, TumCG↓, TumMeta↓, eff↑, Bcl-2↓, cMyc↓, Snail↓, ALDH↓, Myc↓, AR↓, ROS↑, NF-kB↓, PTCH1↓, Smo↓, Gli1↓, GLI2↓, Wnt↓, mTOR↓, GSK‐3β↓, cycD1/CCND1↓, survivin↓, P21↑, p27↑, CHOP↑, Ca+2↑, DNAdam↑, Hif1a↓, VEGF↓, angioG↓, MMP↓, ATP↓, p‑P53↑, γH2AX↑, ChemoSen↑,
5002- Sal,  SFN,    Salinomycin and Sulforaphane Exerted Synergistic Antiproliferative and Proapoptotic Effects on Colorectal Cancer Cells by Inhibiting the PI3K/Akt Signaling Pathway in vitro and in vivo
- in-vivo, CRC, Caco-2 - vitro+vivo, CRC, CX-1
Apoptosis↑, PI3K↓, Akt↓, P53↑, BAX↑, Bax:Bcl2↑, p‑PARP↑, TumCMig↓,
5127- Sal,    Salinomycin repressed the epithelial–mesenchymal transition of epithelial ovarian cancer cells via downregulating Wnt/β-catenin pathway
- in-vitro, Ovarian, NA
TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Wnt↓, β-catenin/ZEB1↓, TumCP↓, TumCMig↓, EMT↓,
1209- SANG,    Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration
- in-vitro, Lung, A549
VEGF↓, TumCMig↓, Akt↓, p38↓,
5139- SAS,    Sulfasalazine induces ferroptosis in osteosarcomas by regulating Nrf2/SLC7A11/GPX4 signaling axis
- in-vitro, OS, MG63 - in-vitro, OS, U2OS
*Inflam↓, TumCP↓, TumCMig↓, Apoptosis↑, Ferroptosis↑, Iron↑, MDA↑, ROS↑, GSH↓, SOD↓, MMP↓, NRF2↓, xCT↓, GPx4↓, FTH1↓,
3198- SFN,    Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells
- in-vitro, Pca, NA
Nanog↓, SOX2↓, E-cadherin↓, Snail↓, VEGFR2↓, Diff↓, TumCMig↓, EMT↓, CXCR4↓, NOTCH1↓, ALDH1A1↓, CSCs↓, eff↑,
1136- SFN,    Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells
- in-vitro, Lung, NA - in-vivo, NA, NA
TumCMig↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Snail↓, ERK5↑, EMT↓,
111- SFN,    Sulforaphene Interferes with Human Breast Cancer Cell Migration and Invasion through Inhibition of Hedgehog Signaling
- in-vitro, BC, SUM159
HH↓, Gli1↓, MMP2↓, MMP9↓, Smo↓, TumCMig↓, TumCI↓,
2166- SFN,    Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction
- in-vitro, Oral, NA - in-vivo, NA, NA
CSCs↓, selectivity↑, TumCMig↓, TumCI↓,
1466- SFN,    Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway
- vitro+vivo, Thyroid, FTC-133
TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, Slug↓, Twist↓, MMP2↓, MMP9↓, TumCG↓, p‑Akt↓, P21↑, ERK↑, p38↑, ROS↑, *toxicity∅, MMP↓, eff↓,
1462- SFN,    Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells
- in-vitro, Bladder, T24/HTB-9
EMT↓, TumCI↓, TumCMig↓, E-cadherin↑, Zeb1↓, Snail↓, COX2↝, MMP2↝, MMP9↝,
1499- SFN,    Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway
- in-vitro, BC, NA
TumCMig↓, TumCI↓, FAK↓, p‑MEK↓, p‑ERK↓,
3326- SIL,    Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway
- in-vitro, Liver, HepG2 - in-vitro, Liver, Hep3B
*hepatoP↑, chemoPv↑, ChemoSen↑, TumCP↓, TumCMig↓, TumCI↓, Hif1a↓, VEGF↓, angioG↓,
3330- SIL,    Mechanistic Insights into the Pharmacological Significance of Silymarin
- Review, Var, NA
*neuroP↑, *hepatoP↑, *cardioP↑, *antiOx↓, *NLRP3↓, *NAD↑, ROS↓, NLRP3↓, TumCMig↓, *COX2↓, *iNOS↓, *MPO↓, *AChE↓, *LDH↓, *Telomerase↓, *Fas↓,
3322- SIL,    Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression
- in-vitro, Lung, A549 - in-vitro, Lung, H1299 - in-vitro, Lung, H460
HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, HDAC8↓, HATs↑, Zeb1↓, E-cadherin↑, TumCMig↓,
3306- SIL,  Rad,    Radioprotective and radiosensitizing properties of silymarin/silibinin in response to ionizing radiation
- Review, Var, NA
radioP↑, RadioS↑, TumCMig↓, TumCI↓, angioG↓, Apoptosis↑, DNAdam↓, ROS↑, *ROS↓, *Inflam↓,
3296- SIL,    Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway
- in-vitro, Oral, Ca9-22 - in-vivo, Oral, YD10B
TumCP↓, TumCCA↑, ROS↑, SOD1↓, SOD2↓, *JNK↑, toxicity?, TumCMig↓, TumCI↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, P53↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, SOD↓,
3290- SIL,    A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents
- Analysis, Var, NA
hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1/CCND1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27↑, cycE/CCNE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
1276- SIL,    Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells
- in-vitro, BC, NA - in-vitro, Thyroid, NA
TumCMig↓, MMP9↓, p‑MEK↓, p‑ERK↓,
1127- SIL,    Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓, RHBDD1↓,
2417- SK,    Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H446
TumCP↓, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, PFKFB2↓, Warburg↓, GLUT1∅, LDHA∅, PKM2∅, GLUT3∅, PDH∅,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2360- SK,    Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway
- in-vitro, NPC, HONE1 - in-vitro, NPC, SUNE-1
TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, ATP↓, PKM2↓, PI3K↓, Akt↓, MMP3↓, MMP9↓, TIMP1↑,
2234- SK,    Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1
- in-vitro, GC, NA
TumCP↓, TumCI↓, TumCMig↓, cMyc↓, YAP/TEAD↓,
2232- SK,    Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis
- in-vitro, ESCC, EC9706
tumCV↓, TumCMig↓, TumCI↓, TumAuto↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, AMPK↑, mTOR↑, TumVol↓, OS↑, LC3I↑,
2190- SK,    Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway
- in-vitro, HCC, HCCLM3
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↓, ROS↑, OCR↓, ATP↓, PKM2↓,
2183- SK,    Shikonin Inhibites Migration and Invasion of Thyroid Cancer Cells by Downregulating DNMT1
- in-vitro, Thyroid, TPC-1
TumCMig↓, TumCI↓, PTEN↑, DNMT1↓,
2182- SK,  Cisplatin,    Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway
- in-vitro, Lung, A549 - in-vitro, Lung, PC9 - in-vivo, NA, NA
tumCV↓, TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, PKM2↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, ChemoSen↑, TumVol↓, TumW↓, GLUT1↓,
2203- SK,    Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation
- in-vitro, Lung, NA
TumCP↓, Apoptosis↓, TumCMig↓, TumCI↓, Ferroptosis↑, ERK↓, GPx4↓, 4-HNE↑, ROS↑, GSH↓, ATF3↑, HDAC1↓, ac‑Histones↑,
2210- SK,    Shikonin inhibits the cell viability, adhesion, invasion and migration of the human gastric cancer cell line MGC-803 via the Toll-like receptor 2/nuclear factor-kappa B pathway
- in-vitro, BC, MGC803
TumCA↓, TumCI↓, TumCMig↓, MMP2↓, MMP7↓, TLR2↓, p65↓, NF-kB↓, eff↑, ROS↑,
3045- SK,    Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2)
- in-vitro, PC, MIA PaCa-2
ECAR↓, Glycolysis↓, ATP↓, PKM2↓, TumCMig↓, Ca+2↑, GlucoseCon↓, lactateProd↓, MMP↓, ROS↑,
3046- SK,    Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway
- in-vitro, Lung, A549
TumCP↓, TumCI↓, TumCMig↓, p‑ERK↓, ITGB1↓,
3048- SK,    Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1 - in-vitro, Nor, MCF12A - in-vivo, NA, NA
tumCV↓, selectivity↑, EMT↓, TumCMig↓, TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, β-catenin/ZEB1↓, GSK‐3β↑,
5075- SSE,    Sodium selenite inhibits proliferation and metastasis through ROS‐mediated NF‐κB signaling in renal cell carcinoma
- vitro+vivo, RCC, 786-O
TumCP↓, TumCMig↓, Apoptosis↑, ROS↑, NF-kB↓, eff↓, E-cadherin↑, cl‑Casp3↑, VEGF↓, MMP9↓, EMT↓, MMP↓, mtDam↑, BAX↑, Bcl-2↓,
5331- TFdiG,    Anti-Cancer Properties of Theaflavins
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, BAX↑, Bcl-2↓, p‑Akt↓, p‑mTOR↓, PI3K↓, cMyc↓, P53↑, ROS↑, NF-kB↓, MMP9↓, MMP2↓, TumVol↓, PSA↓, TumCCA↑, VEGF↓, Hif1a↓, CDK2↓, CDK4↓, GSH↓, Dose↑, BioAv↓, BioAv↓, BioAv↑,
5334- TFdiG,    Theaflavin inhibits the malignant phenotype of human anaplastic thyroid cancer 8305C cells by regulating lipid metabolism via PI3K/AKT signaling
- in-vitro, Thyroid, 8505C
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, Casp3↑, Casp8↑, Casp9↑, survivin↓, SREBP1↓, toxicity↑,
5337- TFdiG,    Theaflavin 3,3'-digallate suppresses metastasis and reduces insulin-like growth factor-1-induced cancer stemness and invasiveness in human melanoma cells
- in-vitro, Melanoma, A375 - in-vitro, Melanoma, A2058
TumCMig↓, TumCI↓, MMPs↓, ALDH↓, CSCs↓, ABCG2↓, CD44↓, CXCR4↓, TumCG↓, angioG↓, TumMeta↓,
962- TQ,    Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways
- in-vitro, PC, PANC1 - in-vitro, Nor, hTERT-HPNE - in-vitro, PC, AsPC-1 - in-vitro, PC, Bxpc-3
TumCMig↓, TumCI↓, Apoptosis↑, Hif1a↓, PI3k/Akt/mTOR↓, TumCCA↑, *toxicity↓, *TumCI∅, *TumCMig∅,
2127- TQ,    Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways
- Review, GBM, NA
chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, eff↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,
3411- TQ,    Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone
- Review, Var, NA
p‑STAT3↓, cycD1/CCND1↓, JAK2↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MET↓, p‑Akt↓, p‑mTOR↓, CXCR4↓, Bcl-2↓, BAX↑, ROS↑, Cyt‑c↑, Twist↓, Zeb1↓, E-cadherin↑, p‑p38↑, p‑MAPK↑, ERK↑, eff↑, ERK↓, TumCP↓, TumCMig↓, TumCI↓,
3421- TQ,    Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer
- Analysis, Nor, NA - in-vivo, Nor, NA - in-vitro, BC, MCF-7 - in-vitro, Nor, HaCaT
HDAC↓, P21↑, Maspin↑, BAX↑, B2M↓, TumCCA↑, selectivity↑, *toxicity↓, TumCMig↓, TumCP↓,

Showing Research Papers: 301 to 350 of 368
Prev Page 7 of 8 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 368

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

4-HNE↑, 1,   antiOx↑, 1,   ATF3↑, 1,   CYP1A1↓, 1,   Ferroptosis↑, 2,   GPx4↓, 2,   GSH↓, 4,   Iron↑, 1,   MDA↑, 1,   NRF2↓, 1,   ROS↓, 4,   ROS↑, 15,   ROS⇅, 1,   SOD↓, 2,   SOD1↓, 1,   SOD2↓, 1,   TrxR1↓, 1,   xCT↓, 1,  

Metal & Cofactor Biology ⓘ

FTH1↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 5,   EGF↓, 1,   MEK↓, 1,   p‑MEK↓, 2,   MMP↓, 9,   mtDam↑, 1,   OCR↓, 1,   Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cMyc↓, 5,   ECAR↓, 1,   GlucoseCon↓, 4,   Glycolysis↓, 2,   ac‑Histones↑, 1,   lactateProd↓, 4,   LDHA∅, 1,   PDH∅, 1,   PFKFB2↓, 1,   PI3k/Akt/mTOR↓, 1,   PKM2↓, 5,   PKM2∅, 1,   SIRT1↓, 1,   SREBP1↓, 2,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 7,   p‑Akt↓, 4,   Apoptosis↓, 1,   Apoptosis↑, 18,   ATF2↓, 1,   BAX↑, 9,   Bax:Bcl2↑, 1,   Bcl-2↓, 9,   Casp↑, 2,   Casp3↑, 3,   cl‑Casp3↑, 4,   cl‑Casp7↑, 1,   Casp8↑, 2,   cl‑Casp8↑, 2,   Casp9↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 3,   Ferroptosis↑, 2,   GRP58↓, 1,   iNOS↓, 1,   p‑JNK↑, 1,   p‑MAPK↑, 1,   Myc↓, 1,   Necroptosis↑, 1,   necrosis↑, 1,   p27↑, 4,   p38↓, 1,   p38↑, 1,   p‑p38↑, 2,   RIP1↓, 1,   survivin↓, 4,   Telomerase↓, 2,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

HATs↑, 2,   p‑pRB↓, 1,   tumCV↓, 6,   tumCV↑, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,  

Autophagy & Lysosomes ⓘ

BNIP3↑, 1,   LC3I↑, 1,   TumAuto↑, 3,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,   DNAdam↑, 2,   DNMT1↓, 1,   GADD45A↑, 1,   P53↑, 4,   p‑P53↑, 1,   p‑PARP↑, 1,   cl‑PARP↑, 5,   PCNA↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 2,   CDK4↓, 3,   cycD1/CCND1↓, 3,   cycE/CCNE↓, 2,   P21↑, 6,   RB1↑, 1,   TumCCA↓, 1,   TumCCA↑, 10,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 2,   ALDH1A1↓, 1,   CD44↓, 2,   CSCs↓, 4,   Diff↓, 1,   EMT↓, 11,   ERK↓, 6,   ERK↑, 2,   p‑ERK↓, 4,   ERK5↑, 1,   Gli1↓, 3,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   HDAC↓, 3,   HDAC1↓, 2,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC8↓, 1,   HH↓, 2,   IGFBP3↑, 1,   mTOR↓, 4,   mTOR↑, 1,   p‑mTOR↓, 2,   Nanog↓, 1,   NOTCH↓, 1,   NOTCH1↓, 2,   PI3K↓, 7,   PTCH1↓, 1,   PTEN↑, 2,   RAS↓, 1,   Smo↓, 2,   SOX2↓, 1,   Src↓, 1,   STAT3↓, 2,   p‑STAT3↓, 1,   TumCG↓, 4,   Wnt↓, 3,  

Migration ⓘ

CA↓, 1,   Ca+2↑, 3,   E-cadherin↓, 2,   E-cadherin↑, 9,   FAK↓, 3,   GLI2↓, 1,   ITGB1↓, 1,   MET↓, 1,   miR-203↑, 1,   MMP2↓, 6,   MMP2↝, 1,   MMP3↓, 1,   MMP7↓, 2,   MMP9↓, 8,   MMP9↝, 1,   MMPs↓, 3,   N-cadherin↓, 4,   N-cadherin↑, 1,   PDGF↓, 1,   RHBDD1↓, 1,   RIP3↓, 1,   Slug↓, 1,   Snail↓, 5,   TGF-β↓, 1,   TIMP1↑, 1,   TumCA↓, 1,   TumCI↓, 31,   TumCMig↓, 49,   TumCMig↑, 1,   TumCP↓, 22,   TumCP↑, 1,   TumMeta↓, 2,   Twist↓, 2,   uPA↓, 2,   Vim↓, 5,   Vim↑, 1,   Zeb1↓, 4,   ZO-1↑, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 5,   EGFR↓, 2,   p‑EGFR↓, 1,   Hif1a↓, 6,   LOX1↓, 1,   VEGF↓, 8,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,   GLUT1∅, 1,   GLUT3∅, 1,   NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

B2M↓, 1,   COX2↓, 4,   COX2↝, 1,   CXCR4↓, 4,   IFN-γ↓, 1,   IL1↓, 2,   IL1β↓, 1,   Inflam↓, 1,   JAK2↓, 1,   NF-kB↓, 7,   p65↓, 2,   PD-1↓, 1,   PD-L1↓, 2,   PGE2↓, 1,   PSA↓, 3,   TLR2↓, 1,   TNF-α↓, 1,   TNF-α↑, 1,  

Protein Aggregation ⓘ

NLRP3↓, 2,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,  

Drug Metabolism & Resistance ⓘ

ABCG2↓, 1,   BioAv↓, 5,   BioAv↑, 2,   ChemoSen↑, 5,   Dose↑, 1,   Dose↝, 1,   eff↓, 2,   eff↑, 6,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 1,   RadioS↑, 3,   selectivity↑, 5,  

Clinical Biomarkers ⓘ

AR↓, 2,   B2M↓, 1,   EGFR↓, 2,   p‑EGFR↓, 1,   Maspin↑, 1,   Myc↓, 1,   PD-L1↓, 2,   PSA↓, 3,  

Functional Outcomes ⓘ

AntiCan↑, 3,   cardioP↑, 1,   CardioT↓, 1,   chemoP↓, 1,   chemoP↑, 3,   chemoPv↑, 1,   hepatoP↑, 2,   MKI67↑, 1,   OS↑, 1,   radioP↑, 1,   RenoP↑, 1,   toxicity?, 1,   toxicity↑, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 3,   TumW↓, 1,  
Total Targets: 249

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 2,   lipid-P↓, 1,   MPO↓, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis ⓘ

LDH↓, 1,   NAD↑, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Fas↓, 1,   iNOS↓, 1,   JNK↑, 1,   Telomerase↓, 1,  

Migration ⓘ

TIMP1↓, 1,   TumCI∅, 1,   TumCMig∅, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL8↓, 1,   Inflam↓, 3,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Clinical Biomarkers ⓘ

LDH↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   hepatoP↑, 2,   neuroP↑, 1,   toxicity↓, 3,   toxicity∅, 1,  
Total Targets: 26

Scientific Paper Hit Count for: TumCMig, Tumor cell migration
21 Curcumin
13 Quercetin
13 Shikonin
11 Berberine
10 Capsaicin
10 Honokiol
9 Silymarin (Milk Thistle) silibinin
8 Apigenin (mainly Parsley)
8 Resveratrol
8 EGCG (Epigallocatechin Gallate)
8 Betulinic acid
8 Magnolol
8 Magnetic Fields
8 Sulforaphane (mainly Broccoli)
7 Ashwagandha(Withaferin A)
7 Thymoquinone
7 Urolithin
6 Propolis -bee glue
6 Chlorogenic acid
6 Fisetin
6 Piperlongumine
6 Rosmarinic acid
5 Silver-NanoParticles
5 Alpha-Lipoic-Acid
5 Artemisinin
5 Baicalein
5 Carvacrol
5 Metformin
5 Phenethyl isothiocyanate
5 Piperine
4 Astragalus
4 Gemcitabine (Gemzar)
4 Astaxanthin
4 Boron
4 Luteolin
4 Pterostilbene
3 Radiotherapy/Radiation
3 Berbamine
3 Bacopa monnieri
3 brusatol
3 Caffeic acid
3 Chrysin
3 Deguelin
3 Ferulic acid
3 Garcinol
3 HydroxyTyrosol
3 Lycopene
3 salinomycin
3 Aflavin-3,3′-digallate
2 Allicin (mainly Garlic)
2 Andrographis
2 Arctigenin
2 Baicalin
2 Bufalin/Huachansu
2 Genistein (soy isoflavone)
2 Boswellia (frankincense)
2 Paclitaxel
2 Carnosic acid
2 Celecoxib
2 Celastrol
2 Chlorophyllin
2 Docetaxel
2 5-fluorouracil
2 Disulfiram
2 Copper and Cu NanoParticles
2 Ellagic acid
2 Emodin
2 Ginkgo biloba
2 Grapeseed extract
2 Juglone
2 Plumbagin
2 Magnetic Field Rotating
2 Nimbolide
2 Psoralidin
2 Cisplatin
2 Parthenolide
2 Ursolic acid
2 Vitamin C (Ascorbic Acid)
2 VitK3,menadione
1 Auranofin
1 Ajoene (compound of Garlic)
1 dibenzyl trisulphide(DTS) from Anamu
1 Aspirin -acetylsalicylic acid
1 Atorvastatin
1 Aloe anthraquinones
1 Biochanin A
1 Bevacizumab (brand Avastin)
1 Brucea javanica
1 Bromelain
1 selenomethionine
1 Bruteridin(bergamot juice)
1 Butyrate
1 Caffeic Acid Phenethyl Ester (CAPE)
1 Cannabidiol
1 chitosan
1 Selenium NanoParticles
1 Citric Acid
1 Oxaliplatin
1 Docosahexaenoic Acid
1 diet Short Term Fasting
1 Evodiamine
1 erastin
1 Fucoidan
1 Shilajit/Fulvic Acid
1 Gambogic Acid
1 Ginger/6-Shogaol/Gingerol
1 γ-linolenic acid (Borage Oil)
1 Graviola
1 Proanthocyanidins
1 Hydrogen Gas
1 HydroxyCitric Acid
1 Indole-3-carbinol
1 Licorice
1 Melatonin
1 doxorubicin
1 immunotherapy
1 Myricetin
1 Naringin
1 Niclosamide (Niclocide)
1 Oroxylin A
1 Orlistat
1 Propyl gallate
1 temozolomide
1 isoflavones
1 raloxifen
1 tamoxifen
1 Germacranolide
1 Rutin
1 Sanguinarine
1 Sulfasalazine
1 Selenite (Sodium)
1 Thymol-Thymus vulgaris
1 Arsenic trioxide
1 Zinc
1 β‐Elemene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:326  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page